ALNY – Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.ALNY
$401.80Name : Alnylam Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $52,667,539,456.00
EPSttm : -2.45
Alnylam Pharmaceuticals, Inc.
$401.80
2.44%$9.56Float Short %
2.71
Margin Of Safety %
Put/Call OI Ratio
0.97
EPS Next Q Diff
0.98
EPS Last/This Y
3.92
EPS This/Next Y
3.79
Price
401.8
Target Price
418.89
Analyst Recom
1.77
Performance Q
57.49
Relative Volume
1.79
Beta
0.25
Ticker: ALNY
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | ALNY | 325.26 | 1.04 | 1.21 | 12865 |
| 2025-07-07 | ALNY | 324.06 | 1.05 | 2.55 | 12879 |
| 2025-07-08 | ALNY | 317.5 | 1.05 | 0.72 | 12953 |
| 2025-07-09 | ALNY | 320.76 | 1.05 | 0.09 | 13345 |
| 2025-07-10 | ALNY | 322.5 | 1.02 | 0.94 | 13527 |
| 2025-07-11 | ALNY | 314.76 | 1.01 | 0.30 | 13538 |
| 2025-07-14 | ALNY | 315.7 | 1.01 | 0.73 | 13575 |
| 2025-07-15 | ALNY | 311.05 | 1.01 | 1.38 | 13766 |
| 2025-07-16 | ALNY | 322.29 | 1.02 | 0.73 | 13761 |
| 2025-07-17 | ALNY | 324.8 | 1.02 | 1.40 | 13721 |
| 2025-07-18 | ALNY | 320.54 | 1.03 | 0.03 | 13876 |
| 2025-07-21 | ALNY | 320.6 | 1.03 | 0.77 | 11939 |
| 2025-07-22 | ALNY | 325.32 | 1.03 | 1.40 | 12137 |
| 2025-07-23 | ALNY | 325.7 | 1.03 | 0.66 | 12148 |
| 2025-07-24 | ALNY | 329 | 1.00 | 0.26 | 12348 |
| 2025-07-25 | ALNY | 329.01 | 0.94 | 0.77 | 12914 |
| 2025-07-28 | ALNY | 324.99 | 0.94 | 1.33 | 12976 |
| 2025-07-29 | ALNY | 330.81 | 0.97 | 0.05 | 13199 |
| 2025-07-30 | ALNY | 339.77 | 0.93 | 0.43 | 13570 |
| 2025-07-31 | ALNY | 391.17 | 0.89 | 1.00 | 14436 |
| 2025-08-01 | ALNY | 401.59 | 0.97 | 1.01 | 15465 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | ALNY | 331.91 | -109.6 | 277.0 | 1.03 |
| 2025-07-07 | ALNY | 324.21 | -109.6 | 275.0 | 1.03 |
| 2025-07-08 | ALNY | 317.50 | -109.6 | 275.2 | 1.03 |
| 2025-07-09 | ALNY | 320.87 | -109.6 | 277.3 | 1.03 |
| 2025-07-10 | ALNY | 322.64 | -109.6 | 277.0 | 1.03 |
| 2025-07-11 | ALNY | 314.94 | -109.6 | 275.3 | 1.03 |
| 2025-07-14 | ALNY | 315.72 | -109.6 | 276.8 | 1.03 |
| 2025-07-15 | ALNY | 311.12 | -109.6 | 275.6 | 1.03 |
| 2025-07-16 | ALNY | 322.86 | -109.6 | 279.2 | 1.03 |
| 2025-07-17 | ALNY | 324.69 | -109.6 | 277.0 | 1.03 |
| 2025-07-18 | ALNY | 320.50 | -109.6 | 275.7 | 1.03 |
| 2025-07-21 | ALNY | 320.70 | -109.6 | 276.6 | 1.03 |
| 2025-07-22 | ALNY | 325.43 | -109.6 | 277.6 | 1.03 |
| 2025-07-23 | ALNY | 325.64 | -109.6 | 276.7 | 1.03 |
| 2025-07-24 | ALNY | 328.00 | -77.2 | 277.1 | 1.56 |
| 2025-07-25 | ALNY | 328.81 | -77.2 | 276.8 | 1.56 |
| 2025-07-28 | ALNY | 325.10 | -77.2 | 275.8 | 1.56 |
| 2025-07-29 | ALNY | 330.55 | -77.2 | 277.8 | 1.56 |
| 2025-07-30 | ALNY | 339.80 | -77.2 | 278.5 | 1.56 |
| 2025-07-31 | ALNY | 392.24 | -77.2 | 409.9 | 1.56 |
| 2025-08-01 | ALNY | 401.80 | -74.0 | 386.9 | 1.74 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | ALNY | -2.84 | 1.55 | 2.71 |
| 2025-07-07 | ALNY | -2.84 | 1.55 | 2.71 |
| 2025-07-08 | ALNY | -2.84 | 1.55 | 2.71 |
| 2025-07-09 | ALNY | -2.84 | 1.55 | 2.71 |
| 2025-07-10 | ALNY | -2.84 | 1.55 | 2.71 |
| 2025-07-11 | ALNY | -2.84 | 1.55 | 2.67 |
| 2025-07-14 | ALNY | -2.84 | 1.68 | 2.67 |
| 2025-07-15 | ALNY | -2.84 | 1.68 | 2.67 |
| 2025-07-16 | ALNY | -2.85 | 1.68 | 2.67 |
| 2025-07-17 | ALNY | -2.85 | 1.68 | 2.67 |
| 2025-07-18 | ALNY | -2.85 | 1.68 | 2.67 |
| 2025-07-21 | ALNY | -2.85 | 1.64 | 2.67 |
| 2025-07-22 | ALNY | -2.85 | 1.64 | 2.67 |
| 2025-07-23 | ALNY | -2.85 | 1.64 | 2.67 |
| 2025-07-24 | ALNY | -2.85 | 1.64 | 2.67 |
| 2025-07-25 | ALNY | -2.66 | 1.64 | 2.71 |
| 2025-07-28 | ALNY | -2.66 | 1.47 | 2.71 |
| 2025-07-29 | ALNY | -2.66 | 1.47 | 2.71 |
| 2025-07-30 | ALNY | -1.78 | 1.47 | 2.71 |
| 2025-07-31 | ALNY | -1.78 | 1.47 | 2.71 |
| 2025-08-01 | ALNY | -1.78 | 1.47 | 2.71 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.44
Avg. EPS Est. Current Quarter
-0.05
Avg. EPS Est. Next Quarter
0.54
Insider Transactions
-1.78
Institutional Transactions
1.47
Beta
0.25
Average Sales Estimate Current Quarter
636
Average Sales Estimate Next Quarter
753
Fair Value
Quality Score
43
Growth Score
47
Sentiment Score
99
Actual DrawDown %
0.2
Max Drawdown 5-Year %
-42.5
Target Price
418.89
P/E
Forward P/E
99.36
PEG
P/S
21.28
P/B
210.01
P/Free Cash Flow
EPS
-2.47
Average EPS Est. Cur. Y
1.74
EPS Next Y. (Est.)
5.54
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
-12.96
Relative Volume
1.79
Return on Equity vs Sector %
-257.4
Return on Equity vs Industry %
-238.7
EPS 1 7Days Diff
0.2
EPS 1 30Days Diff
0.72
EBIT Estimation
386.9
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2230
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading